How many drugs treat Incomplete passage of stool?

Drug Landscape tracks 9 marketed treatments for Incomplete passage of stool (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/incomplete-passage-of-stool.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Incomplete passage of stool — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Incomplete passage of stool (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Incomplete passage of stool, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cholbam	CHOLIC ACID	Mirum	Bile Acid [EPC]	G-protein coupled bile acid receptor 1	2015-01-01
Halflytely	BISACODYL	Braintree	Stimulant Laxative [EPC]	Kappa-type opioid receptor	2004-01-01
Osmoprep	sodium phosphate, monobasic, monohydrate	Salix Pharms	Calculi Dissolution Agent [EPC]		2000-01-01
Renacidin	MAGNESIUM CARBONATE	United Guardian	Vitamin C [EPC]		1990-01-01
Miralax	Macrogol	Braintree	Osmotic Laxative [EPC]		1984-01-01
Prepopik	MAGNESIUM OXIDE	Baxter	magnesium oxide		1982-01-01
Micro-K 10	POTASSIUM CHLORIDE	Nesher Pharms	potassium chloride	Carbonic anhydrase 4	1965-01-01
Milk of Magnesia	magnesium hydroxide	Generic (multiple manufacturers)	Osmotic laxative, Antacid	Gastric acid (direct neutralization) + osmotic effect in intestine	1880-01-01
Cholbam	Cholbam	Mirum Pharmaceuticals, Inc.		G-protein coupled bile acid receptor 1, Bile acid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Incomplete passage of stool
Braintree · 2 drugs in Incomplete passage of stool
Generic (multiple manufacturers) · 1 drug in Incomplete passage of stool
Mirum · 1 drug in Incomplete passage of stool
Mirum Pharmaceuticals, Inc. · 1 drug in Incomplete passage of stool
Nesher Pharms · 1 drug in Incomplete passage of stool
Salix Pharms · 1 drug in Incomplete passage of stool
United Guardian · 1 drug in Incomplete passage of stool
Baxter · 1 drug in Incomplete passage of stool

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Incomplete passage of stool:

Cite this brief

Drug Landscape (2026). Incomplete passage of stool — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/incomplete-passage-of-stool. Accessed 2026-06-10.

Incomplete passage of stool full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing